Profile data is unavailable for this security.
About the company
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
- Revenue in USD (TTM)13.31m
- Net income in USD-809.24m
- Incorporated2014
- Employees750.00
- LocationRoivant Sciences Ltd7Th Floor, 50 BroadwayLONDON SW1H 0DBUnited KingdomGBR
- Phone+44 12955950
- Websitehttp://roivant.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 11.70bn | 2.80k | -- | 2.92 | 36.81 | 2.81 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Biomarin Pharmaceutical Inc | 3.22bn | 348.90m | 11.87bn | 3.22k | 34.65 | 1.95 | 27.71 | 3.69 | 1.78 | 1.78 | 16.57 | 31.65 | 0.4418 | 0.4726 | 4.11 | 1,000,079.00 | 4.79 | 3.09 | 5.28 | 3.46 | 81.43 | 78.42 | 10.83 | 8.18 | 3.50 | -- | 0.0893 | 0.00 | 12.87 | 11.60 | -18.26 | 138.08 | -4.20 | -- |
| BridgeBio Pharma Inc | 502.08m | -724.93m | 12.89bn | 834.00 | -- | -- | -- | 25.67 | -3.78 | -3.78 | 2.62 | -10.71 | 0.5412 | -- | 6.97 | 602,009.60 | -79.01 | -76.52 | -105.26 | -96.54 | 95.82 | 96.16 | -145.98 | -340.73 | 2.68 | -2.17 | 4.29 | -- | 126.26 | 127.44 | -35.31 | -- | 4.99 | -- |
| Elanco Animal Health Inc | 4.72bn | -232.00m | 13.13bn | 9.40k | -- | 2.00 | 29.30 | 2.78 | -0.4848 | -0.4848 | 9.53 | 13.17 | 0.3631 | 1.28 | 5.62 | 501,595.80 | -1.79 | -2.26 | -2.01 | -2.53 | 54.99 | 55.59 | -4.92 | -7.41 | 1.08 | 1.15 | 0.3803 | -- | 6.22 | 7.59 | -168.64 | -- | -2.35 | -- |
| Neurocrine Biosciences Inc | 2.86bn | 478.60m | 13.27bn | 2.00k | 28.36 | 4.07 | 26.09 | 4.64 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Viatris Inc | 14.12bn | -3.69bn | 17.19bn | 32.00k | -- | 1.14 | -- | 1.22 | -3.10 | -3.10 | 11.96 | 13.13 | 0.3417 | 2.09 | 4.90 | 441,387.50 | -8.93 | -0.1756 | -10.89 | -0.2096 | 39.36 | 40.66 | -26.13 | -0.5768 | 0.793 | 2.79 | 0.4868 | -- | -4.46 | 5.09 | -1,259.42 | -- | -3.10 | -- |
| Incyte Corp | 5.14bn | 1.29bn | 20.15bn | 2.84k | 15.81 | 3.89 | 14.61 | 3.92 | 6.40 | 6.40 | 25.61 | 26.04 | 0.8291 | 4.33 | 5.48 | 1,807,750.00 | 20.75 | 11.34 | 27.83 | 14.38 | 93.26 | 93.92 | 25.03 | 16.48 | 3.25 | -- | 0.0067 | 0.00 | 21.22 | 14.03 | 3,844.96 | -- | -20.67 | -- |
| Roivant Sciences Ltd | 13.31m | -809.24m | 20.71bn | 750.00 | -- | 4.81 | -- | 1,556.15 | -1.17 | -1.17 | 0.0193 | 6.02 | 0.0024 | -- | -- | 17,746.67 | -18.26 | 5.89 | -20.80 | 6.98 | 91.21 | 90.39 | -7,558.42 | 639.97 | -- | -- | 0.00 | 0.00 | -11.19 | -15.56 | -111.69 | -- | -1.32 | -- |
| Moderna Inc | 1.94bn | -2.82bn | 21.16bn | 4.70k | -- | 2.44 | -- | 10.88 | -7.26 | -7.26 | 5.00 | 21.95 | 0.1468 | 4.27 | 7.17 | 413,617.00 | -21.31 | 10.19 | -25.32 | 13.43 | 70.32 | 75.74 | -145.16 | 19.02 | 3.22 | -- | 0.0684 | 0.00 | -39.93 | 19.33 | 20.75 | -- | 24.53 | -- |
| United Therapeutics Corp | 3.18bn | 1.33bn | 22.08bn | 1.40k | 18.06 | 3.10 | 15.55 | 6.94 | 27.90 | 27.90 | 66.48 | 162.60 | 0.4176 | 2.25 | 10.11 | 2,273,357.00 | 17.51 | 14.75 | 19.14 | 16.07 | 87.92 | 89.79 | 41.94 | 39.28 | 6.28 | -- | 0.00 | 0.00 | 10.61 | 16.50 | 11.68 | 20.99 | 54.73 | -- |
| Royalty Pharma plc | 2.38bn | 770.95m | 26.66bn | 100.00 | 25.96 | 4.12 | 29.80 | 11.21 | 1.78 | 1.78 | 4.21 | 11.22 | 0.1257 | -- | 84.52 | 23,781,930.00 | 7.00 | 6.72 | 9.03 | 9.10 | -- | -- | 55.68 | 50.56 | -- | 7.06 | 0.4795 | 50.52 | 5.06 | 2.30 | -10.25 | 9.26 | -4.90 | 24.01 |
| Biogen Inc | 9.89bn | 1.29bn | 28.15bn | 7.50k | 21.78 | 1.54 | 13.58 | 2.85 | 8.81 | 8.81 | 67.37 | 124.45 | 0.3441 | 1.04 | 5.30 | 1,318,747.00 | 4.50 | 6.70 | 5.32 | 7.93 | 75.69 | 78.49 | 13.07 | 17.28 | 2.03 | 5.74 | 0.2562 | 0.00 | 2.22 | -5.96 | -20.79 | -20.22 | -19.60 | -- |
Data as of Mar 02 2026. Currency figures normalised to Roivant Sciences Ltd's reporting currency: US Dollar USD
39.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 65.68m | 9.18% |
| Morgan Stanley Investment Management, Inc.as of 31 Dec 2025 | 54.36m | 7.60% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 38.77m | 5.42% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 37.13m | 5.19% |
| QVT Financial LPas of 13 Feb 2026 | 25.16m | 3.52% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 17.36m | 2.43% |
| UBS Securities LLCas of 31 Dec 2025 | 17.18m | 2.40% |
| Adage Capital Management LPas of 31 Dec 2025 | 10.68m | 1.49% |
| Two Seas Capital LPas of 31 Dec 2025 | 9.79m | 1.37% |
| Rubric Capital Management LPas of 31 Dec 2025 | 9.00m | 1.26% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
